3Young-Hoon Jeong,Kevin P. Bliden,Mark J. Antonino,Ki-Soo Park,Udaya S. Tantry,Paul A. Gurbel.Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies[J].American Heart Journal.2012(1)
4Refai Showkathali,Arun Natarajan.Antiplatelet and Antithrombin Strategies in Acute Coronary Syndrome: State-Of-The-Art Review[J].Current Cardiology Reviews.2012(3)
5Jose Diez,B Lombo.Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes[J].Core Evidence (default).2011(default)
6Stefan James,Axel ?kerblom,Christopher P. Cannon,H?kan Emanuelsson,Steen Husted,Hugo Katus,Allan Skene,Philippe Gabriel Steg,Robert F. Storey,Robert Harrington,Richard Becker,Lars Wallentin.Comparison of ticagrelor, the first reversible oral P2Y 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial[J].American Heart Journal.2009(4)
7Thuy Anh Nguyen,Jean G. Diodati,Chantal Pharand.Resistance to clopidogrel: A review of the evidence[J].Journal of the American College of Cardiology.2005(8)
9Jneid H.The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction(UA/NSTEMI)Guideline:a critical appraisal[J].Methodist Debakey Cardiovasc J,2012,8(3):26-30.
10Kim HS,Cho DY,Park BM,et al.The effect of CYP2C19genotype on the time course of platelet aggregation inhibition after clopidogrel administration[J].J Clin Pharmacol,2014,54(8):850-857.
